TNF alpha Antibody (52B83): sc-52746

TNFα Antibody (52B83) is a mouse monoclonal IgG1 kappa light chain antibody that detects TNFα in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). TNFα (52B83) antibody is available in a non-conjugated form, allowing for versatile experimental use. Tumor necrosis factor alpha (TNFα), also known as cachectin, is a critical pleiotropic cytokine that plays a significant role in mediating immune responses and inflammation. TNFα is primarily produced by immune cells such as lymphocytes, neutrophils, and macrophages, and is essential for the regulation of various physiological processes, including apoptosis, cell proliferation, and differentiation. TNFα interacts with TNF receptors on target cells, leading to a cascade of signaling events that modulate immune responses and promote inflammation. Notably, TNFα and TNFβ share approximately 30% amino acid homology and exhibit similar biological activities, making TNFα a key player in the immune system′s response to infection and disease. Understanding TNFα function is crucial, as TNFα not only contributes to the body′s defense mechanisms but also plays a role in pathological conditions such as autoimmune diseases and cancer, where TNFα dysregulation can lead to detrimental effects.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TNF alpha Antibody (52B83) References:

1. TNF-alpha and TNF-beta gene polymorphisms in systemic sclerosis.  |  Pandey, JP. and Takeuchi, F. 1999. Hum Immunol. 60: 1128-30. PMID: 10600011
2. The role of tumor necrosis factor-alpha (TNF-alpha) in bone resorption present in middle ear cholesteatoma.  |  Vitale, RF. and Ribeiro, Fde A. 2007. Braz J Otorhinolaryngol. 73: 117-21. PMID: 17505610
3. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions.  |  Vilcek, J. and Lee, TH. 1991. J Biol Chem. 266: 7313-6. PMID: 1850405
4. Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach.  |  Kim, HL., et al. 2014. Arch Pharm Res. 37: 662-70. PMID: 24469604
5. Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization.  |  Nedwin, GE., et al. 1985. Nucleic Acids Res. 13: 6361-73. PMID: 2995927
6. Tumor Necrosis Factor-alpha (TNF-α) Enhances miR-155-Mediated Endothelial Senescence by Targeting Sirtuin1 (SIRT1).  |  Guo, Q., et al. 2019. Med Sci Monit. 25: 8820-8835. PMID: 31752013
7. Identification of Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor in Rheumatoid Arthritis Using Network Pharmacology and Molecular Docking.  |  Bai, LL., et al. 2021. Front Pharmacol. 12: 690118. PMID: 34093213
8. Human tumor necrosis factor. Production, purification, and characterization.  |  Aggarwal, BB., et al. 1985. J Biol Chem. 260: 2345-54. PMID: 3871770
9. Cytotoxic effect of TNF and lymphotoxin on T lymphoblasts.  |  Sarin, A., et al. 1995. J Immunol. 155: 3716-8. PMID: 7561073
10. Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response.  |  Qin, Z. and Blankenstein, T. 1995. Cancer Res. 55: 4747-51. PMID: 7585497
11. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin.  |  De Togni, P., et al. 1994. Science. 264: 703-7. PMID: 8171322
12. Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor.  |  Tartaglia, LA., et al. 1993. Cell. 73: 213-6. PMID: 8386591

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-TNF alpha Antibody (52B83) has 587 citations in a variety of scientific publications.

Primary antibodies like Anti-TNF alpha Antibody (52B83) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

TNF alpha Antibody (52B83) Specifications

Alternate Product Name: TNF alpha

Product Clone Name: 52B83

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: TNFα

Epitope Species: human

Product Reactivity/Detection: natural and recombinant TNFα

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: Guinea pig, Chimpanzee, Cynomolgus and Rhesus monkey

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), FCM, ELISA

Vialing Information: Each vial contains 100 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 587 citations in various scientific publications

Available Conjugates/Forms for TNF alpha Antibody (52B83): N/A